rytelo (imetelstat)- low- to intermediate-1 risk myelodysplastic syndromes (mds)
Published 6 days ago • 19 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
3:33
imetelstat: understanding how this drug fights myelodysplastic syndrome (mds) │ pharmacology
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:19
imetelstat for transfusion-dependent r/r mds
-
2:00
imetelstat in heavily-transfused lower-risk r/r mds
-
1:25
imerge subgroup study: imetelstat in patients with lr-mds previously exposed to esas
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
3:46
promising agents under investigation for low and high-risk mds
-
9:38
imetelstat provides durable transfusion independence in lower risk mds group
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
4:10
does imetelstat provide transfusion independence in lower-risk mds?
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
4:12
novel therapies in low-risk mds
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
9:36
imetelstat provides durable transfusion independence in heavily transfused non-del(5q) lr-mds r/...
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
1:27
mtesr™1: standardized medium for the feeder-independent maintenance of hescs & hipscs